Redefining Criteria to Ensure Adequate Sentinel Lymph Node Biopsy With Dual Tracer for Breast Cancer

Redefining Criteria to Ensure Adequate Sentinel Lymph Node Biopsy With Dual Tracer for Breast Cancer

BackgroundFor sentinel lymph node biopsy (SLNB) in patients with breast cancer, the dual tracer of blue dye and radioisotope with the 10% rule that all nodes with radioactive count of 10% or more of the hottest node ex vivo should be removed is widely accepted. However, the cut-off point of radioact...

Full description

Bibliographic Details
Main Authors: Li Xu, Jiqiao Yang, Zhenggui Du, Faqing Liang, Yanyan Xie, Quanyi Long, Jie Chen, Helin Zeng, Qing Lv
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-12-01
Series:Frontiers in Oncology
Subjects:
breast cancer
sentinel lymph node biopsy
radioisotope
methylene blue
10% rule
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.588067/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2020.588067/full

Similar Items